Trailhead Biosystems, a Beachwood, OH-based biotechnology firm which focuses on human cell innovation, raised $20M in funding.
Backers weren’t disclosed.
The corporate intends to make use of the funds to reinforce its portfolio of iPSC-derived cells for analysis functions, advancing preclinical drug discovery and illness modeling.
Led by CEO, CSO and Founder Jan Jensen, Trailhead Biosystems leverages a proprietary high-dimensional design of experiments (HD-DoE®) platform for regenerative drugs and drug discovery exactly differentiating induced pluripotent stem cells (iPSCs) into practical human cell varieties.
The corporate lately launched TrailBio® Vascular Leptomeningeal Cells (VLMCs) for blood-brain barrier analysis, addressing a essential want in neuroscience and drug supply.
Trailhead additionally has an workplace in Koendall Sq., Cambridge, MA.
FinSMEs
10/05/2025
